Oncobit wins CHF 150,000 to advance personalized cancer care
21.01.2022
Oncobit wants to enable physicians to deliver the technological advances of the precision medicine revolution to their cancer patients. The startup develops cancer-specific tests that allow doctors to precisely characterize and monitor every individual cancer. The test results then empower oncologists to prescribe the best treatment for each patient. Oncobit will use the CHF 150,000 to obtain regulatory approval for its cancer diagnostics and monitoring products and launch them on the European market.
 The Oncobit team
|
 |
Every cancer is different, but diagnostic tests are rarely cancer-specific. Follow-up visits are cumbersome, and the interpretation of diagnostic tests and treatment options can be overwhelming. Existing diagnostic tests do not provide enough information to optimally treat cancer in a personalized manner, which is a critical factor for patients’ health and well-being.
Oncobit develops next-generation cancer care: The startup’s diagnostic and monitoring tests aim to provide a detailed understanding of genomic cancer alterations throughout the patient’s history. This knowledge allows physicians to make treatment decisions specific to each patient’s cancer. Oncobit addresses the rapidly expanding market of precision oncology and personalized disease monitoring using non-invasive technologies. The startups will initially focus on melanoma, which affects 300,000 patients worldwide every year, but Oncobit’s data-centric approach ensures that all tests are scalable and adaptable to other types of cancer.
Oncobit was founded by a group of physicians and scientists at the University Hospital Zurich and ETHZ, with experience in cancer, life science, and startup entrepreneurship, who teamed up to make a difference in personalized cancer care. The spin-off is spearheaded by CEO Dr. Claudia Scheckel. The funding from Venture Kick allows Oncobit to obtain regulatory approval for its cancer diagnostics and monitoring products and launch them on the European market. The startup aims to obtain ISO13485 certification and CE marking of its first product in the upcoming months. This will allow Oncobit to launch its personalized melanoma monitoring in Switzerland shortly afterward.
“Aside from the visibility and financial contributions we obtained from Venture Kick, we really appreciated the feedback during the boot camps and the jury sessions. Venture Kick helped us to prepare for challenges and reach important milestones, and it accompanied us through several critical stages—from fundraising to ISO certification,” said Oncobit CEO Dr. Claudia Scheckel.
The Oncobit team
Oncobit develops next-generation cancer care: The startup’s diagnostic and monitoring tests aim to provide a detailed understanding of genomic cancer alterations throughout the patient’s history. This knowledge allows physicians to make treatment decisions specific to each patient’s cancer. Oncobit addresses the rapidly expanding market of precision oncology and personalized disease monitoring using non-invasive technologies. The startups will initially focus on melanoma, which affects 300,000 patients worldwide every year, but Oncobit’s data-centric approach ensures that all tests are scalable and adaptable to other types of cancer.
Oncobit was founded by a group of physicians and scientists at the University Hospital Zurich and ETHZ, with experience in cancer, life science, and startup entrepreneurship, who teamed up to make a difference in personalized cancer care. The spin-off is spearheaded by CEO Dr. Claudia Scheckel. The funding from Venture Kick allows Oncobit to obtain regulatory approval for its cancer diagnostics and monitoring products and launch them on the European market. The startup aims to obtain ISO13485 certification and CE marking of its first product in the upcoming months. This will allow Oncobit to launch its personalized melanoma monitoring in Switzerland shortly afterward.
“Aside from the visibility and financial contributions we obtained from Venture Kick, we really appreciated the feedback during the boot camps and the jury sessions. Venture Kick helped us to prepare for challenges and reach important milestones, and it accompanied us through several critical stages—from fundraising to ISO certification,” said Oncobit CEO Dr. Claudia Scheckel.
The Oncobit team